Evolutionary Tree Capital Management’s Charles River Laboratories CRL Stock Holding History

Evolutionary Tree Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,650	Closed	-$1.19M	–	34
2023 Q2	$1.19M	Buy	5,650 +4	+0.1%	+$796	1.43%	27
2023 Q1	$1.14M	Sell	5,646 -9,889	-64%	-$2.24M	1.58%	24
2022 Q4	$3.39M	Sell	15,535 -1,429	-8%	-$312K	3.25%	12
2022 Q3	$3.34M	Buy	16,964 +4,098	+32%	+$885K	3.21%	12
2022 Q2	$2.75M	Buy	+12,866	New	+$3.14M	3%	13

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Evolutionary Tree Capital Management's CRL Position: Q3 2023 in Review

Evolutionary Tree Capital Management sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 5,650 shares — an estimated $1.19M sold.

Evolutionary Tree Capital Management first reported a position in CRL in Q2 2022 and held it in 5 quarters. The position peaked at $3.39M in Q4 2022. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Evolutionary Tree Capital Management reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
Evolutionary Tree Capital Management sold 5,650 Charles River Laboratories shares in Q3 2023, an estimated $1.19M.
Evolutionary Tree Capital Management first reported a position in Charles River Laboratories in Q2 2022 and held it in 5 quarters.
Evolutionary Tree Capital Management's Charles River Laboratories position peaked at $3.39M in Q4 2022.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Evolutionary Tree Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.